Countervail Corporation


Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development

Countervail is pleased to announce the receipt of a $225,000 SBIR Phase I grant award from the National Institutes of Health / National Institute of Neurological Disorders and Stroke (NIH/NINDS). The grant is to support early stage development of a novel diagnostic test for the detection and quantitation of organophosphate toxin exposure. Organophosphate toxins consist of a long list of pesticides such as chlorpyrifos, malathion and diazinon as well as military nerve agents such as sarin, soman and VX.  Countervail’s unique test design offers substantial benefits over current methods of evaluating exposure to these toxic compounds.